Healthcare ❯ Pharmaceuticals ❯ Clinical Trials

Drug Development

Weight Loss Treatment Elinzanetant Eli Lilly Azelaprag Obesity Treatments Vibozilimod Oveporexton Phase 3 Trials Personalized Medicine Enlicitide Tolebrutinib Rare Diseases

Sanofi Ends PPMS Bid After Tolebrutinib Fails Phase 3 as FDA Delays Review for nrSPMS

The program narrows to non‑relapsing secondary progressive MS, with the U.S. decision now expected by the end of the first quarter of 2026.

Viking Therapeutics Jumps After Wider Q3 Loss as R&D Ramp Signals Obesity-Drug Progress